Analysis of the Predictive Value of Peripheral Blood miR-155 Levels for the Clinical Efficacy of Immunoglobulin Therapy in Children with Kawasaki Disease
GONG Haitao, MA Xiaomiao
Ankang Maternal and Child Health Hospital,Ankang Shaanxi 725000
Abstract：【Objective】To explore the predictive value of peripheral blood miR-155 levels for the clinical efficacy of immunoglobulin therapy in children with Kawasaki disease.【Methods】A total of 187 children with KD admitted to the hospital from October 2018 to March 2021 were selected as the study subjects. They were divided into a sensitive group (n=162) and a non responsive group (n=25) based on their clinical efficacy within 14 days after treatment. The factors affecting the clinical efficacy of KD children were analyzed, and the predictive value of the relative expression level of miR-155 in peripheral blood before treatment on the clinical efficacy of immunoglobulin therapy in KD children was analyzed. 【Results】After treatment, 25 out of 187 children with KD (13.37%) showed no response to immunoglobulin. Non reactive group alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transpeptidase,total bilirubin,the relative expression levels of hypersensitive C-reactive protein, erythrocyte sedimentation rate, troponin I, N-terminal B-type brain natriuretic peptide(NT-proBNP), and miR-155 were higher in the sensitive group than in the sensitive group (P<0.05). Logistic regression analysis showed that the relative expression level of miR-155 and NT-proBNP were related factors affecting the clinical efficacy of immunoglobulin therapy in children with KD (P<0.05). ROC curve analysis showed that the optimal cutoff point, sensitivity, specificity, and area under the curve for evaluating the clinical efficacy of immunoglobulin therapy in KD children with peripheral blood miR-155 relative expression were 3.01%, 76.00%, 80.25%, and 0.785, respectively (P<0.05). 【Conclusion】Children with KD have a high risk of immunoglobulin non response, and miR-155 is associated with the clinical efficacy of immunoglobulin therapy in KD patients. miR-155 has a higher predictive effect on the clinical efficacy of immunoglobulin therapy in KD patients.
龚海涛, 马小苗. 外周血miR-155水平对免疫球蛋白治疗川崎病患儿临床疗效的预测价值[J]. 医学临床研究, 2023, 40(12): 1878-1881.
GONG Haitao,MA Xiaomiao. Analysis of the Predictive Value of Peripheral Blood miR-155 Levels for the Clinical Efficacy of Immunoglobulin Therapy in Children with Kawasaki Disease. JOURNAL OF CLINICAL RESEARCH, 2023, 40(12): 1878-1881.
[1] NOVAL RIVAS M, ARDITI M. Kawasaki disease: pathophysiology and insights from mouse models[J].Nat Rev Rheumatol,2020, 16(7):391-405. [2] FULLER M G. Kawasaki disease in infancy[J].Adv Emerg Nurs J, 2019, 41(3):222-228. [3] BARTEL D P. Metazoan microRNAs[J].Cell,2018, 173(1):20-51. [4] WITTEN L, SLACK F J. miR-155 as a novel clinical target for hematological malignancies[J].Carcinogenesis,2020, 41(1):2-7. [5] KUMRAH R, VIGNESH P, RAWAT A, et al. Immunogenetics of kawasaki disease[J].Clin Rev Allergy Immunol,2020, 59(1):122-139. [6] MCCRINDLE B W, ROWLEY A H, NEWBURGER J W, et al. Diagnosis, treatment, and long-term management of kawasaki disease: A scientific statement for health professionals from the American Heart Association[J].Circulation,2017, 135(17):927-999. [7] MIYATA K, KANEKO T, MORIKAWA Y, et al. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study[J].Lancet Child Adolesc Health,2018, 2(12):855-862. [8] HAMADA H, SUZUKI H, ONOUCHI Y, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial[J].Lancet,2019, 393(10176):1128-1137. [9] TIRELLI F, MARRANI E, GIANI T, et al. One year in review: Kawasaki disease[J].Curr Opin Rheumatol,2020, 32(1):15-20. [10] WANG J,LU J,DONG S B,et al. An ultrasensitive electrochemical biosensor for detection of microRNA-21 based on redox reaction of ascorbic acid/iodine and duplex-specific nuclease assisted target recycling[J].Biosens Bioelectron,2019, 130(1):81-87. [11] READHEAD B, HAURE-MIRANDE J V, MASTROENI D, et al. miR-155 regulation of behavior, neuropathology, and cortical transcriptomics in Alzheimer's disease[J].Acta Neuropathol,2020, 140(3):295-315. [12] KOROTKOV A, PUHAKKA N, GUPTA S D, et al. Increased expression of miR142 and miR-155 in glial and immune cells after traumatic brain injury may contribute to neuroinflammation via astrocyte activation[J].Brain Pathol,2020, 30(5):897-912. [13] 陈婷婷, 卢亚亨, 石坤, 等. 心率变异性、心率减速力与静脉注射免疫球蛋白无反应川崎病的相关性[J].中华实用儿科临床杂志, 2021, 36(1):23-27.
2023, Vol. 40 
